PMID- 37324230
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230619
IS  - 2322-5718 (Print)
IS  - 2322-5726 (Electronic)
IS  - 2322-5718 (Linking)
VI  - 11
IP  - 2
DP  - 2023
TI  - Metabolic tumor parameters complement clinicopathological factors in 
      prognosticating advanced stage Hodgkin Lymphoma.
PG  - 111-121
LID - 10.22038/AOJNMB.2023.69260.1482 [doi]
AB  - OBJECTIVES: Advanced Hodgkin Lymphoma has a higher probability of relapse and 
      recurrence. Classical clinicopathological parameters including the International 
      Prognostic Score (IPS) have not been reliable in predicting prognosis or 
      tailoring treatment. Since FDG PET/CT is the standard of care in staging Hodgkin 
      Lymphoma, this study attempted to evaluate the clinical utility of baseline 
      metabolic tumor parameters in a cohort of advanced Hodgkin lymphoma (stage III 
      and IV). METHODS: Histology-proven advanced Hodgkin Patients presenting to our 
      institute between 2012-2016 and treated with chemo-radiotherapy (ABVD / AEVD) 
      were followed up till 2019. Quantitative PET/CT and clinicopathological 
      parameters were used to estimate the Event Free Survival (EFS) in 100 patients. 
      Kaplan-Meier method with log-rank test was used to compare the survival times of 
      prognostic factors. RESULTS: At a median follow-up of 48.83 months 
      (IQR:33.31-63.05 months), the five-year-EFS was 81%. Of the 100 patients, 16 had 
      relapsed (16%) and none died at the last follow-up. On Univariate analysis, among 
      non-PET parameters bulky disease (P=0.03) and B-symptoms (P=0.04) were 
      significant while among PET/CT parameters SUV(max) (p=0.001), SUV(mean) 
      (P=0.002), WBMTV2.5 (P<0.001), WBMTV41% (P<0.001), WBTLG2.5 (P<0.001) and 
      WBTLG41% (P <0.001) predicted poorer EFS. 5-year EFS for patients with low 
      WBMTV2.5 [<1038.3 cm3] was 89% and 35% for patients with high WBMTV2.5 [>/=1038.3 
      cm3] (p <0.001). In a multivariate model, only WBMTV2.5 (P=0.03) independently 
      predicted poorer EFS. CONCLUSION: PET-based metabolic parameter (WBMTV2.5) was 
      able to prognosticate and complement the classical clinical prognostic factors in 
      advanced Hodgkin Lymphoma. This parameter could have a surrogate value for 
      prognosticating advanced Hodgkin lymphoma. Better prognostication at baseline 
      translates to tailored or risk-modified treatment and hence higher survival.
FAU - Mohite, Ashish
AU  - Mohite A
AD  - Department of Nuclear medicine and Molecular Imaging, Tata Memorial Centre, 
      Mumbai Maharashtra, India.
AD  - Homi Bhabha National Institute, Anushaktinagar, Mumbai, Maharashtra, India.
FAU - Rangarajan, Venkatesh
AU  - Rangarajan V
AD  - Department of Nuclear medicine and Molecular Imaging, Tata Memorial Centre, 
      Mumbai Maharashtra, India.
AD  - Homi Bhabha National Institute, Anushaktinagar, Mumbai, Maharashtra, India.
FAU - Goda, Jayant
AU  - Goda J
AD  - Department of Radiation Oncology, Tata Memorial Centre, Mumbai Maharashtra, 
      India.
AD  - Homi Bhabha National Institute, Anushaktinagar, Mumbai, Maharashtra, India.
FAU - Chugh, Swati
AU  - Chugh S
AD  - Department of Radiation Oncology, Tata Memorial Centre, Mumbai Maharashtra, 
      India.
AD  - Homi Bhabha National Institute, Anushaktinagar, Mumbai, Maharashtra, India.
FAU - Agrawal, Archi
AU  - Agrawal A
AD  - Department of Nuclear medicine and Molecular Imaging, Tata Memorial Centre, 
      Mumbai Maharashtra, India.
AD  - Homi Bhabha National Institute, Anushaktinagar, Mumbai, Maharashtra, India.
FAU - Sengar, Manju
AU  - Sengar M
AD  - Department of Haematooncology, Tata Memorial Centre, Mumbai Maharashtra, India.
AD  - Homi Bhabha National Institute, Anushaktinagar, Mumbai, Maharashtra, India.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Asia Ocean J Nucl Med Biol
JT  - Asia Oceania journal of nuclear medicine & biology
JID - 101611092
PMC - PMC10261693
OTO - NOTNLM
OT  - 18F-FDG PET/ CT
OT  - Advanced Hodgkin's lymphoma
OT  - Clinicopathological parameters
OT  - Event free survival
OT  - Metabolic tumor parameters
COIS- Authors declare no conflict of interest.
EDAT- 2023/06/16 06:42
MHDA- 2023/06/16 06:43
PMCR- 2023/01/01
CRDT- 2023/06/16 04:08
PHST- 2022/12/03 00:00 [received]
PHST- 2023/01/21 00:00 [revised]
PHST- 2023/01/28 00:00 [accepted]
PHST- 2023/06/16 06:43 [medline]
PHST- 2023/06/16 06:42 [pubmed]
PHST- 2023/06/16 04:08 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.22038/AOJNMB.2023.69260.1482 [doi]
PST - ppublish
SO  - Asia Ocean J Nucl Med Biol. 2023;11(2):111-121. doi: 
      10.22038/AOJNMB.2023.69260.1482.